Company Encyclopedia
View More
name
Science Sun Pharm
300485.SZ
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, among others. It is also involved in the research, development, production, and sale of raw materials; the extraction of traditional Chinese medicine; and the manufacture of Chinese and Western medicine preparations. In addition, the company is engaged in livestock and poultry breeding; the research, development, and sale of biological organic fertilizers; and the research and development of biological feed.
1.585 T
300485.SZMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking46/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE2.41%C
    • Profit Margin20.19%A
    • Gross Margin66.92%A
  • Growth ScoreC
    • Revenue YoY-0.84%D
    • Net Profit YoY142.34%A
    • Total Assets YoY2.47%C
    • Net Assets YoY2.36%C
  • Cash ScoreC
    • Cash Flow Margin495.33%C
    • OCF YoY-0.84%D
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio4.75%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Science Sun Pharm: Net profit in the third quarter was 4.0733 million yuan, a decrease of 41.41%

    Science Sun Pharm announced that its revenue for the third quarter was 112 million yuan, a year-on-year increase of 3.50%; net profit was 4.0733 million yuan, a decrease of 41.41%. Revenue for the first three quarters was 309 million yuan, a year-on-year decrease of 4.41%; net profit was 51.8596 million yuan, a year-on-year increase of 152.81%

    Zhitong·
    SZ
    300485
    +0.61%
    Zhitong·
    SZ
    300485
    +0.61%

    Science Sun Pharm shareholders Ma Li and Liu Shuqin plan to collectively reduce their holdings by no more than 2%

    According to the Zhitong Finance APP, Science Sun Pharm announced that the company's shareholders, Ms. Ma Li and Ms. Liu Shuqin, plan to reduce their holdings of the company's shares by a total of no more than 9.6333 million shares, through centralized bidding and block trading, from October 21, 2025, to January 20, 2026, which is no more than 2% of the company's current total share capital

    Zhitong·
    SZ
    300485
    +0.61%
    Zhitong·
    SZ
    300485
    +0.61%

    Science Sun Pharm: In the first half of 2025, net profit was 47.7862 million yuan, a year-on-year increase of 145.45%

    Science Sun Pharm announced that in the first half of 2025, operating revenue was 197 million yuan, a year-on-year decrease of 8.40%. Net profit was 47.7862 million yuan, compared to a loss of 105 million yuan in the same period last year, representing a year-on-year increase of 145.45%

    Zhitong·
    SZ
    300485
    +0.61%
    Zhitong·
    SZ
    300485
    +0.61%

    China Science Sun Pharm is in talks to authorize weight loss drugs in the United States. (Reuters)

    Wallstreetcn·
    SZ
    300485
    +0.61%
    Wallstreetcn·
    SZ
    300485
    +0.61%

    The monoclonal antibody concept was active at the beginning of the trading session, with Science Sun Pharm and HAINAN HAIYAO both rising over 9%, while YILING PHARMACEUTICAL, Zhongyuan Union, and FUDANZHANGJIANG also saw gains

    Zhitong·
    SH
    688505
    +0.36%
    HK
    01349
    -0.34%
    SZ
    300485
    +0.61%
    Zhitong·
    SH
    688505
    +0.36%
    HK
    01349
    -0.34%
    SZ
    300485
    +0.61%
    © 2025 Longbridge｜Disclaimer